share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GUYER DAVID R

SEC announcement ·  Jul 16 16:28
Summary by Moomoo AI
On July 12, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. Subsequently, Guyer sold 11,625 shares on the open market at a price of $10.0641 per share. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 1,850 shares. The total market value of the disposed shares amounted to approximately $116,995.16.
On July 12, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. Subsequently, Guyer sold 11,625 shares on the open market at a price of $10.0641 per share. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 1,850 shares. The total market value of the disposed shares amounted to approximately $116,995.16.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more